Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines

Clinical Therapeutics

Volumn 21, Issue 6, 1999, Pages 1025-1044

  Meunier, Pierre J ^a   Delmas, Pierre D ^a   Eastell, Richard ^b   McClung, Michael R ^c   Papapoulos, Socrates ^d   Rizzoli, Rene ^e   Seeman, Ego ^g   Wasnich, Richard D ^f  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

^c OREGON OSTEOPOROSIS CENTER   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITAL   (Switzerland)

^f Hawaii Osteoporosis Center   (United States)

^g NONE

Author keywords

Bone mineral density; Fracture; Osteoporosis; Postmenopausal

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; ESTROGEN; ETIDRONIC ACID; FLUORIDE; GESTAGEN; IPRIFLAVONE; PLACEBO; RALOXIFENE; STEROID; VITAMIN D;

ARTICLE; BONE DEMINERALIZATION; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DIET SUPPLEMENTATION; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HIGH RISK POPULATION; HOT FLUSH; HUMAN; INTRANASAL DRUG ADMINISTRATION; LABORATORY TEST; OSTEOPOROSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; VEIN THROMBOSIS;

EID: 0032772281     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80022-8     Document Type: Article

References (104)

1. 1. Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Am J Med. 1991;90:107-110.
2. 2. Melton LJ III. How many women have osteoporosis now? J Bone Miner Res. 1995;10:175-177.
3. 3. Kanis JA, Geusens P, Christiansen C. Guidelines for clinical trials in osteoporosis: A position paper of the European Foundation for Osteoporosis and Bone Disease. Osteoporosis Int. 1991;1:182-188.
4. 4. Jones G, Nguyen T, Sambrook PN, et al. Symptomatic fracture incidence in elderly men and women: The Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporosis Int. 1994;4:277-282.
5. 5. Ross PD. Osteoporosis: Frequency, consequences, and risk factors. Arch Intern Med. 1996;156:1399-1411.
6. 6. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med. 1997;103(Suppl 2A):12S-19S.
7. 7. Gold DT. The clinical impact of vertebral fractures: Quality of life in women with osteoporosis. Bone. 1996;18(Suppl 3): 185S-189S.
8. 8. Melton LJ III, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993;8:1227-1233.
9. 9. Lauritzen JB, Schwarz P, Lund B, et al. Changing incidence and residual lifetime risk of common osteoporosis-related fractures. Osteoporosis Int. 1993;3:127-132.
10. 10. Ross PD, Genant HK, Davis JW, et al. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporosis Int. 1993;3:120-127.
11. 11. Ensrud KE, Lipschutz RC, Cauley JA, et al. Body size and hip fracture risk in older women: A prospective study. Am J Med. 1997;103:274-280.
12. 12. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991;114:919-923.
13. 13. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. NEJM. 1995;332:767-773.
14. 14. Cooper C. Epidemiology of vertebral fractures in Western populations. In: Cooper C, Reeve J, eds. Spine. State of the Art Reviews: Vertebral Osteoporosis. Vol. 8. Philadelphia: Hanley and Belfus; 1994: 1-21.
15. 15. Schurch MA, Rizzoli R, Mermillod B, et al. A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res. 1996;11:1935-1942.
16. 16. Poor G, Atkinson EJ, O'Fallon WM, Melton LJ III. Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res. 1995;319:260-265.
17. 17. Poor G, Atkinson EJ, Lewallen DG, et al. Age-related hip fractures in men: Clinical spectrum and short-term outcomes. Osteoporosis Int. 1995;5:419-426.
18. 18. Browner WS, Pressman AR, Nevitt MC, Cummings SR. Mortality following fractures in older women. The Study of Osteoporotic Fractures. Arch Intern Med. 1996;156:521-525.
19. 19. Marotolli RA, Berkman LF, Cooney LM. Decline in physical function following hip fracture. J Am Geriatr Soc. 1992;40: 861-866.
20. 20. Cummings SR, Phillips SL, Wheat ME, et al. Recovery of function after hip fracture. J Am Geriatr Soc. 1988;36:801-806.
21. 21. Magaziner J, Simonsick EM, Kashner TM, et al. Predictors of functional recovery one year following hospital discharge for hip fracture: A prospective study. J Gerontol Biol Sci Med Sci. 1990;45:M101-M107.
22. 22. Mossey JM, Mutran E, Knott K, et al. Determinants of recovery 12 months after hip fracture: The importance of psychosocial factors. Am J Public Health. 1989; 79:279-285.
23. 23. Jalovaara P, Virkkunen H. Quality of life after hemiarthroplasty for femoral neck fracture. Acta Orthop Scand. 1991;62:208-217.
24. 24. Kanis JA, Delmas P, Burckhardt P, et al, on behalf of the European Foundation for Osteoporosis and Bone Disease. Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int. 1997;7:390-406.
25. 25. Seeley DG, Browner WS, Nevitt MC, et al. Which fractures are associated with low appendicular bone mass in elderly women? Ann Intern Med. 1991;115:837-842.
26. 26. Phillips S, Fox N, Jacobs J, Wright WE. The direct medical costs of osteoporosis for American women aged 45 and older. Bone. 1988;9:271-279.
27. 27. Ross PD. Clinical consequences of vertebral fractures. Am J Med. 1997;103(Suppl 2A):30S-43S.
28. 28. Cook DJ, Guyatt GH, Adachi JD, et al. Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum. 1993;36:750-756.
29. 29. Huang C, Ross PD, Wasnich RD. Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med. 1996;156:2469-2475.
30. 30. Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: A prospective study. Ann Intern Med. 1998;128:793-800.
31. 31. Leidig-Bruckner G, Minne HW, Schlaich C, et al. Clinical grading of spinal osteoporosis: Quality of life components and spinal deformity in women with chronic low back pain and women with vertebral osteoporosis. J Bone Miner Res. 1997; 12:663-675.
32. 32. Ross PD, Ettinger B, Davis JW, et al. Evaluation of adverse health outcomes associated with vertebral fractures. Osteoporosis Int. 1991;1:134-140.
33. 33. Melton LJ III. Epidemiology of agerelated fractures. In: Avioli LV, ed. The Osteoporotic Syndrome. Detection, Prevention, and Treatment. 3rd ed. New York: Wiley-Liss; 1993:17-38.
34. 34. Chrischilles EA, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone. 1994;15:377-386.
35. 35. Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone. 1992;13(Suppl 1):S7-SI5.
36. 36. Greendale GA, Barrett-Connor E, Ingles S, et al. Late physical activity and functional effects of osteoporotic fracture in women: The Rancho Bernardo Study. J Am Geriatr Soc. 1995;43:955-961.
37. 37. Huang C, Ross PD, Wasnich RD. Vertebral fractures and other predictors of back pain among older women. J Bone Miner Res. 1996;11:1025-1031.
38. 38. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: A worldwide projection. Osteoporosis Int. 1992;2:285-289.
39. 39. Looker AC, Wahner HW, Dunn WL, et al. Proximal femur bone mineral levels of US adults. Osteoporosis Int. 1995;5:389-409.
40. 40. Harris S, Dawson-Hughes B. Rates of change in bone mineral density of the spine, heel, femoral neck and radius in healthy postmenopausal women. J Bone Miner Res. 1992;17:87-95.
41. 41. Ensrud KE, Palermo L, Black DM, et al. Hip and calcaneal bone loss increase with advancing age: Longitudinal results from the study of osteoporotic fractures. J Bone Miner Res. 1995;10:1778-1787.
42. 42. Riggs BL, Wahner HW, Seeman E, et al. Changes in bone mineral density of the proximal femur and spine with aging: Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest. 1982;70:716-723.
43. 43. Kanis JA, and the World Health Organization Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. Osteoporosis Int. 1994;4:368-381.
44. 44. Schott AM, Cormier C, Hans D, et al. How hip and whole body bone mineral density predict hip fracture in elderly women. The EPIDOS prospective study. Osteoporosis Int. 1998;8:247-254.
45. 45. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
46. 46. Delmas PD, Beaudreuil J. Biochemical markers of bone turnover in osteoporosis. J Clin Rheumatol. 1997;3:211-216.
47. 47. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Belle Mead, NJ: Excerpta Medica, Inc.; 1998.
48. 48. Eastell R. Forearm fracture. Bone. 1996; 18(Suppl 3):203S-207S.
49. 49. Lydick E, Cook C, Turpin J, et al. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Managed Care. 1998;4:37-48.
50. 50. Johnell O, Gullberg B, Kanis JA, et al. Risk factors for hip fracture in European women: The MEDOS study. J Bone Miner Res. 1995;10:1802-1815.
51. 51. Reid IR. Glucocorticoid-induced osteoporosis and other forms of secondary osteoporosis. In: Meunier PJ, ed. Osteoporosis: Diagnosis and Management. London: Martin Dunitz; 1998;233-250.
52. 52. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res. 1996;11:1531-1538.
53. 53. Nelson DA, Molloy R, Kleerekoper M. Prevalence of osteoporosis in women referred for bone density testing. J Clin Densitom. 1999;1:5-11.
54. 54. Riis BJ, Hansen MA, Jensen AM, et al. Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15-year follow-up study. Bone. 1996;19:9-12.
55. 55. Kotowicz MA, Melton LJ III, Cooper C, et al. Risk of hip fracture in women with vertebral fracture. J Bone Miner Res. 1994;9:599-605.
56. 56. Lauritzen JB, Lund B. Risk of hip fracture after osteoporosis fractures. 451 women with fracture of lumbar spine, olecranon, knee or ankle. Acta Orthop Scand. 1993;64:297-300.
57. 57. Bonnick SL. The prediction of fracture risk with densitometry. In: Bone Densitometry in Clinical Practice. Totowa, NJ: Humana Press; 1998:111-126.
58. 58. Frost HM. Personal experience in managing acute compression fractures, their aftermath, and the bone pain syndrome in osteoporosis. Osteoporosis Int. 1998;8:13-15.
59. 59. Lauritzen JB. Hip fractures: Incidence, risk factors, energy absorption, and prevention. Bone. 1996;18(Suppl 1):65S-75S.
60. 60. Elders PJM, Lips P, Netelenbos JC, et al. Long term effect of calcium supplementation on bone loss in peri-menopausal women. J Bone Miner Res. 1994;9:963-970.
61. 61. Recker RR, Hinders S, Davies KM, et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res. 1996;11:1961-1966.
62. 62. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. NEJM. 1997;337:670-676.
63. 63. Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med. 1996;124:400-406.
64. 64. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. NEJM. 1992;327:1637-1642.
65. 65. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ. 1994; 308:1081-1082.
66. 66. Eastell R. Treatment of postmenopausal osteoporosis. NEJM. 1998;338:736-746.
67. 67. Meunier PJ. Evidence-based medicine and osteoporosis: A comparison of fracture risk reduction data from osteoporosis randomised clinical trials. Int J Clin Pract. 1999;53:122-129.
68. 68. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. NEJM. 1995; 333:1437-1443.
69. 69. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996; 348:1535-1541.
70. 70. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate: A meta-analysis. JAMA. 1997; 277:1159-1164.
71. 71. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
72. 72. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med. 1985;102:319-324.
73. 73. Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. NEJM. 1993;329:1141-1146.
74. 74. Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women. NEJM. 1987; 317:1169-1174.
75. 75. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. NEJM. 1980;303:1195-1198.
76. 76. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
77. 77. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. NEJM. 1990;322:1265-1271.
78. 78. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. NEJM. 1990;323:73-79.
79. 79. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med. 1993;95:557-567.
80. 80. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: A doseresponse study. BMJ. 1992;305:556-561.
81. 81. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts are no better at preventing vertebral fractures than calcium - vitamin D in postmenopausal osteoporosis: The FAVOS study. Osteoporosis Int. 1998; 8:4-12.
82. 82. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. NEJM. 1990;322:802-809.
83. 83. Pak CYC, Sakhaee K, Piziak V, et al. Slow-release sodium fluoride in the management of postmenopausal osteoporosis: A randomized controlled trial. Ann Intern Med. 1994;120:625-632.
84. 84. Tilyard MW, Spears GFS, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. NEJM. 1992;326:357-362.
85. 85. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Intern Med. 1990;113:649-655.
86. 86. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1996;276:1389-1396.
87. 87. Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99: 144-152.
88. 88. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone. 1995;17:383-390.
89. 89. Bone HG, Downs RW, Tucci JR, et al. Doseresponse relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab. 1997;82:265-274.
90. 90. Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. NEJM. 1998;338:485-492.
91. 91. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann Intern Med. 1998;128:253-261.
92. 92. De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. NEJM. 1996;335:1016-1021.
93. 93. Alendronate (Fosamax®). Physicians' Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Company, Inc.; 1999: 1795-1799.
94. 94. Watts N, Freedholm D, Daifotis A. Alendronate from the laboratory to the patient: Clinical tolerability profile of alendronate. Int J Clin Pract. 1999;53(Suppl 101): 51-61.
95. 95. Stock JL, Bell NH, Chesnut CH III, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med. 1997; 103:291-297.
96. 96. Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. Am J Med. 1997;103:468-476.
97. 97. Meunier PJ, Confavreux E, Tupinon I, et al. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab. 1997;82:2784-2791.
98. 98. Pouilles JM, Tremollieres F, Roux C, et al. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporosis Int. 1997;7:213-218.
99. 99. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized study. Am J Med. 1995;99:36-42.
100. 100. Thomas T, LaFage M-H, Alexandre C. Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis. J Rheumatol. 1995; 22:2183-2185.
101. 101. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. NEJM. 1997;337: 1641-1647.
102. 102. Raloxifene (Evista®). Physicians' Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Company, Inc.; 1999: 1576-1579.
103. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int. 1994;54:370-376.
104. 104. Ott SM, Chesnut CH III. Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989;110: 267-274.